New imaging test to measure PARP in metastatic breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a new imaging scan called [18F]FTT PET that may show how much of a protein called PARP is in your tumors. This could help doctors decide if a PARP inhibitor (a type of targeted therapy) is right for you. You may be able to join if you have metastatic breast cancer and are already planning to take a PARP inhibitor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with breast cancer that has spread to other parts of the body (metastatic).
- Your doctor is considering treatment with a PARP inhibitor (alone or with another drug called an immunotherapy).
- You are 18 years or older.
- You are in generally good health (able to do most daily activities, with some help if needed).
- You have a tumor sample from a metastatic site (either already stored or you agree to a new biopsy).
- You are willing to have an extra biopsy and a special PET scan during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses a special PET scan (FTT-PET) and a blood test (ctDNA) to see if they can predict how well PARP inhibitor therapy works in men with metastatic prostate cancer that has specific genetic mutations. It aims to improve treatment decisions by identifying which patients benefit most from these drugs.
This early study uses a special PET/CT scan to see how much a specific cancer-related protein (PARP-1) is present in pheochromocytoma and paraganglioma. It may help doctors understand the biology of these tumors and how useful this scan could be in the future.
This study tests how well an FTT PET/CT scan can detect and measure metastatic (spread) prostate cancer. It may help your care team decide on the best next treatment plan, especially if you need to change or start therapy.
This trial tests whether a special PET scan (FDG PET-CT) can better track how well treatment is working for people with advanced breast cancer. It may help doctors choose the best therapy and monitor response over time.
This trial tests a new PET scan (called FFNP) to see if it can find which breast cancers stop responding to hormone therapy early. It's for people with advanced hormone-receptor-positive breast cancer who are starting a new endocrine treatment.
This trial tests a new imaging technique (18F-FES PET/CT) along with blood markers to guide treatment for metastatic breast cancer that is ER-positive and HER2-negative. It's for people whose cancer progressed on first-line hormone therapy and who are starting a second line of hormone therapy.
Hear when a new Anatomic Stage IV Breast Cancer AJCC v8 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.